Regulation of apoptosis in HL-1 cardiomyocytes by phosphorylation of the receptor tyrosine kinase EphA2 and protection by lithocholic acid

British Journal of Pharmacology

Volumn 167, Issue 7, 2012, Pages 1563-1572

  Jehle, J ^a   Staudacher, I ^a   Wiedmann, F ^a   Schweizer, P A ^a   Becker, R ^a   Katus, H A ^a   Thomas, D ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

apoptosis; atrial fibrillation; cardiac myocyte; EphA2; heart failure

Indexed keywords

CASPASE 3; DOXAZOSIN; EPHRIN RECEPTOR A2; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; LITHOCHOLIC ACID; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; SMALL INTERFERING RNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; HEART MUSCLE CELL; HEART PROTECTION; IN VITRO STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOXAZOSIN; LITHOCHOLIC ACID; MICE; MYOCYTES, CARDIAC; PHOSPHORYLATION; PROTECTIVE AGENTS; RECEPTOR, EPHA2;

EID: 84868632461     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02117.x     Document Type: Article

References (42)

1. Aimé-Sempé C, Folliguet T, Rücker-Martin C, Krajewska M, Krajewska S, Heimburger M, et al,. (1999). Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol 34: 1577-1586.
2. Alexander SP, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
3. Bikou O, Thomas D, Trappe K, Lugenbiel P, Kelemen K, Koch M, et al,. (2011). Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. Cardiovasc Res 92: 218-225.
4. Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM, et al,. (2008). The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 118: 64-78.
5. Cardin S, Li D, Thorin-Trescases N, Leung TK, Thorin E, Nattel S, (2003). Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. Cardiovasc Res 60: 315-325.
6. Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS, (2002). Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 62: 2840-2847.
7. Claycomb WC, Lanson NA, Jr, Stallworth BS, Egeland DB, Delcarpio JB, Bahinski A, et al,. (1998). HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci U S A 95: 2979-2984.
8. Dohn M, Jiang J, Chen X, (2001). Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis. Oncogene 20: 6503-6515.
9. Dries JL, Kent SD, Virag JA, (2011). Intramyocardial administration of chimeric ephrinA1-Fc promotes tissue salvage following myocardial infarction in mice. J Physiol 589: 1725-1740.
10. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE, (2004a). Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness. Biochem Biophys Res Commun 320: 1096-1102.
11. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE, (2004b). EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene 23: 1448-1456.
12. Eiras S, Fernandez P, Pineiro R, Iglesias MJ, Gonzalez-Juanatey JR, Lago F, (2006). Doxazosin induces activation of GADD153 and cleavage of focal adhesion kinase in cardiomyocytes en route to apoptosis. Cardiovasc Res 71: 118-128.
13. Fang WB, Brantley-Sieders DM, Hwang Y, Ham AJ, Chen J, (2008). Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase. J Biol Chem 283: 16017-16026.
14. Gelb BD, Tartaglia M, (2006). Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. Hum Mol Genet 15 (Spec No 2): R220-R226.
15. Giorgio C, Hassan Mohamed I, Flammini L, Barocelli E, Incerti M, Lodola A, et al,. (2011). Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation. PLoS ONE 6: e18128.
16. Goichberg P, Bai Y, D'Amario D, Ferreira-Martins J, Fiorini C, Zheng H, et al,. (2011). The ephrin A1-EphA2 system promotes cardiac stem cell migration after infarction. Circ Res 108: 1071-1083.
17. González-Juanatey JR, Iglesias MJ, Alcaide C, Piñeiro R, Lago F, (2003). Doxazosin induces apoptosis in cardiomyocytes cultured in vitro by a mechanism that is independent of alpha1-adrenergic blockade. Circulation 107: 127-131.
18. Hilfiker-Kleiner D, Landmesser U, Drexler H, (2006). Molecular mechanisms in heart failure. Focus on cardiac hypertrophy, inflammation, angiogenesis, and apoptosis. J Am Coll Cardiol 48: A56-A66.
19. + channels in cell proliferation and apoptosis. Cell Death Dis 2: e193.
20. Kang PM, Izumo S, (2000). Apoptosis and heart failure: a critical review of the literature. Circ Res 86: 1107-1113.
21. Kinch MS, Carles-Kinch K, (2003). Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. Clin Exp Metastasis 20: 59-68.
22. Kozoni V, Tsioulias G, Shiff S, Rigas B, (2000). The effect of lithocholic acid on proliferation and apoptosis during the early stages of colon carcinogenesis: differential effect on apoptosis in the presence of a colon carcinogen. Carcinogenesis 21: 999-1005.
23. Kyprianou N, (2003). Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J Urol 169: 1520-1525.
24. 1-adrenoceptor antagonists: a new mechanism for cancer treatment? Naunyn Schmiedebergs Arch Pharmacol 380: 473-477.
25. Miao H, Burnett E, Kinch M, Simon E, Wang B, (2000). Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol 2: 62-69.
26. Mohammed KA, Wang X, Goldberg EP, Antony VB, Nasreen N, (2011). Silencing receptor EphA2 induces apoptosis and attenuates tumor growth in malignant mesothelioma. Am J Cancer Res 1: 419-431.
27. Nasreen N, Mohammed KA, Antony VB, (2006). Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells. Cancer 107: 2425-2435.
28. Noblitt LW, Bangari DS, Shukla S, Knapp DW, Mohammed S, Kinch MS, et al,. (2004). Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther 11: 757-766.
29. Noblitt LW, Bangari DS, Shukla S, Mohammed S, Mittal SK, (2005). Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy. Cancer Gene Ther 12: 46-53.
30. Rafiq K, Kolpakov MA, Abdelfettah M, Streblow DN, Hassid A, Dell'Italia LJ, et al,. (2006). Role of protein-tyrosine phosphatase SHP2 in focal adhesion kinase down-regulation during neutrophil cathepsin G-induced cardiomyocytes anoikis. J Biol Chem 81: 19781-19792.
31. Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, et al,. (2009). Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther 8: 1027-1034.
32. Shih H, Lee B, Lee RJ, Boyle AJ, (2011). The aging heart and post-infarction left ventricular remodeling. J Am Coll Cardiol 57: 9-17.
33. Soucek R, Thomas D, Kelemen K, Bikou O, Seyler C, Voss F, et al,. (2012). Genetic suppression of atrial fibrillation using a dominant-negative ether-a-go-go-related gene mutant. Heart Rhythm 9: 265-272.
34. + channel-associated cardiac effects of the antidepressant drug desipramine. Naunyn Schmiedebergs Arch Pharmacol 383: 119-139.
35. Tandon M, Vemula SV, Mittal SK, (2011). Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets 15: 31-51.
36. Tandon M, Vemula SV, Sharma A, Ahi YS, Mittal S, Bangari DS, et al,. (2012). EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model. J Gene Med 14: 77-89.
37. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2000). Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 283: 1967-1975.
38. + channels. Eur J Pharmacol 579: 98-103.
39. Trappe K, Thomas D, Bikou O, Kelemen K, Lugenbiel P, Voss F, et al,. (2012). Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3-a preclinical pilot study. Eur Heart J. doi: 10.1093/eurheartj/ehr269.
40. Wu CF, Bishopric NH, Pratt RE, (1997). Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes. J Biol Chem 272: 14860-14866.
41. Wykosky J, Debinski W, (2008). The EphA2 receptor and ephrina1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res 6: 1795-1806.
42. Zhou Z, Yuan X, Li Z, Tu H, Li D, Qing J, et al,. (2008). RNA interference targeting EphA2 inhibits proliferation, induces apoptosis, and cooperates with cytotoxic drugs in human glioma cells. Surg Neurol 70: 562-568.